Latest news with #EHA
Mid East Info
09-07-2025
- Business
- Mid East Info
Deloitte Middle East wins gold at Employee Happiness Awards 2025 - Middle East Business News and Information
Dubai, United Arab Emirates, July 9th, 2025 – Deloitte Middle East received two golden accolades at the Employee Happiness Awards (EHA) UAE 2025: HR Team of the Year and Best Recruitment Strategy. The awards ceremony, held at the Westin Mina Seyahi Hotel in Dubai, celebrated organizations that excel in fostering positive work environments and prioritizing employee well-being. Commenting on the wins, Rana Ghandour Salhab, Deloitte Middle East People & Purpose Managing Partner, said: 'We are honoured to receive these awards, which reflect our dedication to enhancing the employee experience at Deloitte as well as our unwavering commitment to our inclusive policies. At Deloitte we are committed to attracting the best graduates, nationals and experienced talent by creating a workplace where everyone feels valued and empowered to succeed.' The EHA is the only program of its kind in the UAE recognizing excellence with a diligent screening process that includes a live presentation before a jury of CHROs. The accolades Deloitte received highlight the organization's best-in-class talent approach, focused on hiring the finest talent, developing them and building a future-proof workforce. Deloitte's People and Purpose initiatives are designed to provide a healthy work-life balance, fostering flexibility, and a sense of belonging. This is achieved through innovative approaches to talent management, leadership development and recruitment, which aims to build an environment where employees can thrive and contribute meaningfully to the organization, to our clients and also the wider community. – END –
CairoScene
05-07-2025
- Health
- CairoScene
First Phase of Universal Health Insurance Plan Launches in Aswan
UHIS officially launches in Aswan, marking the end of the first rollout phase. Over 2.8 million services delivered in trial run, with national coverage set for completion by 2027. Jul 05, 2025 Egypt has officially launched the Universal Health Insurance System (UHIS) in Aswan, the final governorate in the programme's first implementation phase. The milestone marks a key step toward the full national rollout, which is now scheduled to conclude by 2027. Aswan becomes the sixth governorate to join UHIS - following Port Said, Ismailia, South Sinai, Suez, and Luxor - and the second in Upper Egypt. The system, managed by the Egyptian Healthcare Authority (EHA), delivered over 2.8 million services during its trial phase in Aswan, ranging from medical tests and diagnostics to surgeries and advanced treatment. According to EHA Chairman Ahmed El-Sobky, the services included one million lab tests, 400,000 emergency treatments, 100,000 outpatient visits, and 20,000 surgeries. Nearly half were specialised or advanced-level procedures. Care was delivered through eight hospitals and 89 affiliated clinics. Investments in UHIS infrastructure, equipment, and digital transformation in Aswan have exceeded EGP 12 billion. The first phase of the UHIS, launched in 2018, cost more than EGP 51 billion overall. The second phase - covering Damietta, Marsa Matrouh, Kafr El-Sheikh, North Sinai, and Minya - is expected to begin later this year at an estimated cost of EGP 115 billion.
Associated Press
03-07-2025
- Business
- Associated Press
Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY
- Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY® - - Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world - TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (Nasdaq: VRTX) recently announced positive longer-term data for PrCASGEVY® (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress, continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients more than 6 years, with a mean of 39.4 months and 43.5 months, respectively. CASGEVY is the first authorized CRISPR/Cas9 gene-edited therapy. 'This longer-term data reinforces CASGEVY's durable clinical benefits for eligible people living with sickle cell disease or transfusion-dependent beta thalassemia,' said Kevin Kuo, M.D., Hematologist and Associate Professor in the Division of Hematology, University of Toronto, Clinician Investigator in the Red Blood Cell Disorders Clinic at University Health Network, and Principal Investigator for the CLIMB-131 clinical program. 'These results are a reminder of what science can achieve, especially for patients and communities with significant unmet need.' New longer-term follow-up data presented from the CASGEVY trials Progress in bringing CASGEVY to patients Through reimbursement agreements, Vertex has secured access for eligible SCD or TDT patients in multiple countries including Austria, Bahrain, England, Denmark, the Kingdom of Saudi Arabia, Northern Ireland, Scotland, the United Arab Emirates, the United States and Wales. In Canada, CASGEVY received positive recommendations for reimbursement from both Canadian health technology agencies between December 2024 and January 2025; however, a Letter of Engagement from the pan-Canadian Pharmaceutical Alliance (pCPA) is pending. Vertex is continuing to work with government and reimbursement authorities globally to secure sustainable access for additional eligible patients. About Sickle Cell Disease (SCD) SCD is a debilitating, progressive, life-shortening genetic disease. SCD patients report health-related quality of life scores well below the general population and significant health care resource utilization. SCD affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or 'sickled' red blood cells. The clinical hallmark of SCD is vaso-occlusive crises (VOCs), which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. About Transfusion-Dependent Beta Thalassemia (TDT) TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and significant health care resource utilization. TDT requires frequent blood transfusions and iron chelation therapy throughout a person's life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. About PrCASGEVY® (exagamglogene autotemcel) PrCASGEVY® is an autologous genome edited hematopoietic stem cell-based therapy for eligible patients with SCD or TDT, in which a patient's own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate vaso-occlusive crises (VOCs) for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. About the CLIMB Trials The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12 to 35 years with TDT or with SCD and recurrent VOCs. The trials are closed for enrollment. Patients will be followed for approximately two years after CASGEVY infusion in these trials. Each patient will be asked to participate in the ongoing long-term, open-label trial, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients who received CASGEVY, including those in other CLIMB trials. The trial is designed to follow patients for up to 15 years after CASGEVY infusion. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies in select regions for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Kevin Kuo, M.D., in this press release, and statements regarding expectations for the anticipated durable clinical benefits of CASGEVY, expectations for the safety profile of CASGEVY, expectations for the Letter of Engagement from the pCPA, plans to continue working with government and reimbursement authorities globally to secure sustainable access for patients, and our plans for and design of the CLIMB studies. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that eligible patient access to CASGEVY may not be achieved on the anticipated timeline, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, and other risks listed under the heading 'Risk Factors' in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. Vertex Pharmaceuticals Incorporated Investors: [email protected] Media: Canada: +1 647-790-1600 or U.S.: 617-341-6992 SOURCE Vertex Pharmaceuticals (Canada) Inc.
Yahoo
01-07-2025
- Automotive
- Yahoo
Autolus Therapeutics (AUTL) Presents Positive Long-Term Obe-cel Data at EHA 2025
Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 12, the company presented long-term follow-up data from its FELIX study at the 2025 European Hematology Association (EHA) Congress. The presentation highlighted the potential of obecabtagene autoleucel (obe-cel; brand name Aucatzyl) for long-term remission in adult patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL). A scientist in a lab coat holding a petri dish, the dish containing a 3D multicellular tissue. FELIX is a phase 1b/2, open-label, multicenter, single-arm study evaluating obe-cel in adults with r/r CD19-positive B-ALL. The study investigated obe-cel (formerly AUTO1), an autologous CD19 CAR T-cell therapy designed for rapid CAR T cell expansion and a favorable safety profile. According to the presented data, the estimated 3-year overall survival rate was 55.4%. The data also demonstrated sustained remission rates, with 40% of patients remaining in molecular remission at 36 months. Commenting on the development, Dr. Christian Itin, Autolus CEO, said: 'Obe-cel's durability of response without any subsequent therapy in two out of every five responders is a key factor leading the transformation of therapy for adult r/r B-ALL patients. At a median follow-up of 33 months, we are encouraged to see a continuation of the long-term plateau we observed at the last data cut.' Autolus Therapeutics plc (NASDAQ:AUTL) is a clinical-stage biopharmaceutical company. It develops programmed T cell therapies to treat cancer and autoimmune diseases. Its lead candidate is obe-cel, a CD19-targeting treatment for adult acute lymphoblastic leukemia (ALL). Other pipeline programs include AUTO1/22 (pediatric ALL), AUTO4 (T-cell lymphoma), AUTO6NG (neuroblastoma), and AUTO8 (multiple myeloma). While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Goldman Sachs Energy Stocks: 10 Stocks to Buy and 10 Best AI Stocks to Buy According to Billionaire David Tepper. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Al-Ahram Weekly
01-07-2025
- Health
- Al-Ahram Weekly
Egypt launches Universal Health Insurance System in Aswan - Health
Egypt's Universal Health Insurance System (UHIS) has officially launched in Aswan, marking the final governorate in the first phase of the nationwide programme, according to the Egyptian Healthcare Authority (EHA). Aswan is the sixth governorate to join the UHIS and the second in Upper Egypt after Luxor. The multi-phase programme began in 2018 in Port Said and has since expanded to Ismailia, South Sinai, Suez, and Luxor. EHA Chairman Ahmed El-Sobky stated that during the trial phase, which commenced in late 2023, the system in Aswan provided 2.8 million medical and therapeutic services. These ranged from comprehensive medical exams and diagnostics to advanced treatments and major surgeries. According to El-Sobky, the services included more than one million medical and laboratory tests, 400,000 emergency services, 100,000 outpatient visits, and 20,000 surgeries, with over 45 percent classified as primary, advanced, skilled, or specialised procedures. Intensive care, neonatal services, and other forms of advanced care were also provided. The services were delivered through eight hospitals and 89 family medicine centres and units affiliated with the EHA. El-Sobky stated that investments in the UHIS in Aswan have exceeded EGP 12 billion, encompassing infrastructure, medical equipment, and digital transformation initiatives. He described the system's launch as a step towards 'health justice' and improving public health outcomes. The first phase of the UHIS, which focused on upgrading medical infrastructure, has cost more than EGP 51 billion. The second phase, expected to begin later this year, will extend coverage to Damietta, Marsa Matrouh, Kafr El-Sheikh, North Sinai, and Minya, with an estimated cost of EGP 115 billion, according to Prime Minister Mostafa Madbouly. Originally slated for completion by 2032, the UHIS will be rolled out nationwide by 2027 under presidential directives. Follow us on: Facebook Instagram Whatsapp Short link:
